Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EQ101 · 1 trial · 4 indications
Number of participants with treatment-related adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE)
| Arm | Type | Description |
|---|---|---|
| EQ101 | EXPERIMENTAL | EQ101 weekly |
| Name | Type | Description |
|---|---|---|
| EQ101 | DRUG | EQ101, 2 mg/kg, once weekly dosing, for a total of 24 doses |
Key Inclusion Criteria: 1.Subjects have AA, meeting all of the following criteria: 1. Clinical diagnosis of AA with no other aetiology of hair loss ; 2. At least 35% scalp hair loss, as defined by a SALT score ≥ 35, at Screening and Baseline. Approximately 25% of subjects with 35% to \<50% scalp h...
EQ101 is being developed for the treatment of moderate to severe alopecia areata, an autoimmune condition that causes hair loss. It is an investigational small molecule being studied in adults 18 years and older. Equillium, Inc. is evaluating it in a Phase 2 clinical program.
EQ101 targets CD6, a protein receptor expressed on the surface of T cells. CD6 is involved in T cell activation and trafficking, processes implicated in autoimmune and inflammatory conditions. By binding CD6, EQ101 is designed to modulate T cell activity relevant to alopecia areata.
EQ101 is being developed by Equillium, Inc., a biopharmaceutical company that trades on the Nasdaq under the ticker symbol EQ. Equillium is the sponsor of the clinical program evaluating EQ101 in alopecia areata.
EQ101 is in Phase 2 clinical development for alopecia areata. It is an investigational therapy and has not been approved by the FDA. The Phase 2 study of EQ101 in adults with moderate to severe alopecia areata has been completed.
EQ101 has been studied in one Phase 2 trial, NCT05589610, titled Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata. The trial enrolled 36 adults across Australia and New Zealand and has been completed. It was an uncontrolled study without randomization or blinding.
EQ101 is a small molecule therapeutic candidate. It is being developed as a treatment for alopecia areata, a dermatologic autoimmune condition. Equillium, Inc. is advancing the asset through clinical development, with a completed Phase 2 trial in adults with moderate to severe disease.